Grace Therapeutics, Inc.
GRCE$24M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaPRINCETON6 employees
Drugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Jun 22, 2026
8dMarket Overview
Stock performance and key metrics
GRCE News
Catalyst Timeline
2 upcoming, 0 past
EarningsNext
GRCE Earnings Report
Jun 22, 2026Confirmed
EPS Est: $-0.24 | FQ end 2026-03
1 more catalyst beyond 14 days
Start a 7-day free trial to see all upcoming catalysts
Drug Pipeline
GTX-104
Aneurysmal Subarachnoid Hemorrhage (aSAH)
CaPre
Hypertriglyceridemia
Lipid Lowering Medication
Hypertriglyceridemia
CaPre (TM)
Hypertriglyceridemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GTX-104 | Phase 3 | Aneurysmal Subarachnoid Hemorrhage (aSAH) | - | - |
CaPre | Phase 3 | Hypertriglyceridemia | - | - |
Lipid Lowering Medication | Phase 2 | Hypertriglyceridemia | - | - |
CaPre (TM) | Phase 2 | Hypertriglyceridemia | - | - |
Hypertriglyceridemia
2 drugs in this indication
Aneurysmal Subarachnoid Hemorrhage (aSAH)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply